Amedisys (NASDAQ:AMED) was upgraded by equities research analysts at Royal Bank of Canada from a “sector perform” rating to an “outperform” rating in a research report issued to clients and investors on Monday.
AMED has been the subject of several other research reports. BidaskClub cut Amedisys from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 11th. Oppenheimer upped their price target on Amedisys from $68.00 to $63.00 and gave the stock an “outperform” rating in a research note on Thursday, March 1st. Jefferies Group set a $70.00 price target on Amedisys and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Zacks Investment Research upgraded Amedisys from a “hold” rating to a “buy” rating and set a $66.00 price target for the company in a research note on Tuesday, March 6th. Finally, TheStreet cut Amedisys from a “b” rating to a “c+” rating in a research note on Wednesday, February 28th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Amedisys has a consensus rating of “Buy” and a consensus target price of $63.18.
Shares of Amedisys stock opened at $61.46 on Monday. Amedisys has a 52 week low of $45.60 and a 52 week high of $65.91. The company has a current ratio of 1.45, a quick ratio of 1.45 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $2,131.86, a P/E ratio of 69.84, a PEG ratio of 1.07 and a beta of 0.62.
Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, February 27th. The health services provider reported $0.56 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.58 by ($0.02). Amedisys had a return on equity of 15.14% and a net margin of 1.98%. The company had revenue of $404.24 million for the quarter, compared to analysts’ expectations of $394.96 million. During the same quarter last year, the company earned $0.44 EPS. research analysts forecast that Amedisys will post 3 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. LS Investment Advisors LLC lifted its stake in shares of Amedisys by 233.1% in the 4th quarter. LS Investment Advisors LLC now owns 3,564 shares of the health services provider’s stock valued at $188,000 after purchasing an additional 2,494 shares in the last quarter. NorthCoast Asset Management LLC acquired a new position in shares of Amedisys in the 3rd quarter valued at about $262,000. Fox Run Management L.L.C. acquired a new position in shares of Amedisys in the 4th quarter valued at about $269,000. Paloma Partners Management Co acquired a new position in shares of Amedisys in the 4th quarter valued at about $310,000. Finally, Crossmark Global Holdings Inc. acquired a new position in shares of Amedisys in the 3rd quarter valued at about $341,000. 96.71% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Amedisys (AMED) Stock Rating Upgraded by Royal Bank of Canada” was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.thestockobserver.com/2018/03/21/amedisys-amed-stock-rating-upgraded-by-royal-bank-of-canada.html.
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.